Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts

Prostate

Volumn 36, Issue 3, 1998, Pages 194-200

  Buhler, Kent R ^a   Corey, Eva ^a   Stray, James E ^a   Vessella, Robert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Prostate cancer xenografts; Prostate specific antigen; Serine proteases; Serpins

Indexed keywords

ALPHA 1 ANTITRYPSIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE HOMOLOGY; TUMOR XENOGRAFT;

ANIMALS; HUMANS; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SERINE PROTEINASE INHIBITORS; SERPINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031826559     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980801)36:3<194::AID-PROS8>3.0.CO;2-H     Document Type: Article

References (32)

1. Parker SL, long T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
2. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE: Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 1995;45:729-144.
3. Luderer AA, Chen Y, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R: Measurement of the performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-194.
4. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson P, Stenman U, Dowell B, Lovgren T, Lilja H: Free, complexed and total serum prostate-specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-1095.
5. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
6. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 1990;194:755-763.
7. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SD, Curtis D, Lange PH: Characterization of an androgen sensitive, PSA producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-1048.
8. van Steenbrugge GJ, van Weerden WM, de Ridder CMA, van der Kwast TH, Schroder FH: Development and application of prostatic xenograft models for the study of human prostate cancer. In: Motta M, Serio M (eds): "Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects." Amsterdam: Elsevier; 1994:11-22.
9. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung H, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG: CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-3046.
10. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostate carcinoma. Cancer Res 1983;43:1809-1818.
11. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3: 402-408.
12. Bladou F, Vessella RL, Buhler KR, Ellis WJ, True LD, Lange PH: Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 1996; 67:785-790.
13. Williams BJ, Jones E, Kozlowski JM, Vessella RL, Brothman AR: Comparative genomic hybridization and molecular cytogenetic characterization of two prostate cancer xenografts. Genes Chromosomes Cancer 1997;18:299-304.
14. Gleave ME, Hsieh J, Wu H, von Eschenbach AC, Chung LW: Serum prostate-specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-1605.
15. Lim DJ, Liu XL, Sutkowski DM, Braun EJ, Lee C, Kozlowski JM: Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate 1993;22:108-118.
16. Corey E, Wegner SK, Stray JE, Corey MJ, Arfman EW, Lange PH, Vessella RL: Characterization of 10 new monoclonal antibodies against prostate-specific antigen by analysis of affinity, specificity, and function in sandwich assays. Int J Cancer 1997; 71:1019-1028.
17. Lin DW, Noteboom JL, Blumenstein BA, Ellis WJ, Lange PH, Vessella RL: Serum percent free prostate-specific antigen (f-PSA) in metastatic prostate cancer. Urology 1998 (in press).
18. Ware JL: Prostate cancer progression: Implications of histopathology. Am J Pathol 1994;145:983-993.
19. Warzynski MJ, Soechtig CE, Maatman TJ, Goldsmith LC, Grobbel M, Carothers GG, Shockley KF: DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma-necessitating multiple site analysis. Prostate 1995;27:329-335.
20. Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL: LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. Prostate 1998;35:135-143.
21. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar M, Rittenhouse HG, Wolfert RL, Saedi MS: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710-714.
22. Noldus J, Chen Z, Stamey TA: Isolation and characterization of free form prostate-specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997;158:1606-1609.
23. Young CY, Seay T, Hogen K, Charlesworth MC, Roche PC, Klee GG, Tindall DJ: Prostate-specific human kallikrein (hK2) as a novel marker of prostate cancer. Prostate 1996;7(suppl):17-24.
24. Nathoo SA, Finlay TH: Immunological and chemical properties of mouse α1-protease inhibitors. Arch Biochem Biophys 1986; 246:162-174.
25. Inglis JD, Hill RE: The murine Spi-2 proteinase inhibitor locus: A multigene family with a hypervariable reactive site domain. EMBO J 1991;10:255-261.
26. Hill RE, Shaw PH, Boyd PA, Baumann H, Hastie ND: Protease inhibitors in mouse and man: Divergence within the reactive centre regions. Nature 1984;311:175-177.
27. Sinohara H, Takahara H: Mouse plasma trypsin inhibitors: Isolation and characterization of α-1-antitrypsin and contrapsin, a novel trypsin inhibitor. J Biol Chem 1982;257:438-446.
28. Takahara H, Sinohara H: Inhibitory spectrum of mouse contrapsin and α-1-antitrypsin against mouse serine proteases. J Biochem 1983;93:1411-1419.
29. 1-antichymotrypsin. J Biol Chem 1983;258:12749-12752.
30. Ohkubo K, Ogata S, Misumi Y, Takami N, Sinhara H, Ikehara Y: Cloning, structure and expression of cDNA for mouse contrapsin and a related protein. Biochem J 1991;276:337-342.
31. Irvine J, Newlands GFJ, Huntley JF, Miller HRP: Interaction of murine intestinal mast cell proteinase with inhibitors (serpins) in blood: Analysis by SDS-PAGE and western blotting. Immunology 1990;69:139-144.
32. 1-antichymotrypsin-like proteins in a murine chondrocytic cell line. Gene 1991;106:213-220.